We use cookies necessary to giving you a better online experience. By using our website you consent to all cookies in accordance with our Privacy Policy.
Yes, I accept
Menu
Search Opener
Vienna, Austria

ESTRO 2025

Session

Monday
May 05
15:15 - 16:15
Stolz 2
Urology / Head & Neck
Sandra Nuyts, Belgium;
Simon KB Spohn, Germany
Poster Discussions are presented in one of the sessions scheduled at the two poster discussion theatres. Each author will present a digital poster orally for 2 minutes, followed by 2 minutes for discussion. Sessions will be recorded and made available via the online platfrom and mobile app.
Poster Discussions
Clinical
15:00 - 15:06
Impact on survival of deviations of stereotactic ablative radiotherapy quality in GORTEC 2014-04 IIR trial of oligometastatic HNSCC patients
Juliette Thariat, France
E25-838
15:06 - 15:12
Consequential quality of life sequelae of radiotherapy-induced xerostomia in head and neck cancer: results from the randomized UPGRADE-RT trial
Sven van den Bosch, The Netherlands
E25-1867
15:12 - 15:18
Preliminary results of the CRASCH study: cemiplimab and radiotherapy for cutaneous squamous cell carcinoma of the head and neck
Emma D’Ippolito , Italy
E25-3673
15:18 - 15:24
Performant Multimodal Nasopharyngeal Carcinoma Segmentation with 3D Gaussian-prompted Diffusion Deep Learning Model
Jiarui ZHU, China, Hong Kong Special Administrative Region
E25-3263
15:24 - 15:30
Prognostic Impact of Lymph Node Ratio in Locally Advanced Oral Cancer Patients: Insights from a Randomized Trial Subgroup (NCT00193843)
Anuj Kumar S, India
E25-3223
15:30 - 15:36
Daily Adaptive RadioTherapy in Postoperative HypofrActionated Salvage radiothERapy for prostate cancer patients (DART-PHASER): early results
Luca Nicosia, Italy
E25-2343
15:36 - 15:42
Phase II Study of MR-guided Prostate Stereotactic Body Radiotherapy in Seven Days: toxicity analysis – preliminary results
Benjamin Vanspeybroeck, Belgium
E25-1808
15:42 - 15:48
Development and internal validation of a nomogram predicting ADT-free survival in oligorecurrent prostate cancer treated with metastasis-directed SBRT
Timo Soeterik, The Netherlands
E25-2362
15:48 - 15:54
5 year outcomes of a randomized feasibility study comparing SABR with or without nodal irradiation in high risk prostate cancer (SPORT – NCT03253978)
Nicola Hill, United Kingdom
E25-3770
15:54 - 16:00
PROGNOSTIC ROLE OF PLASMA PROTEOMICS SIGNATURE IN OLIGORECURRENT PROSTATE CANCER PATIENTS UNDERGOING SBRT: RESULTS FROM A PROSPECTIVE TRIAL
Fabio Matrone, Italy
E25-1137